Knowledge Transfer Partnership Sponsored by the Department of Trade & Industry (DTI)

Posted:
4
July 2006

We are pleased to announce that we have launched a unique research project in conjunction with Queen Mary University of London.The Knowledge Transfer Partnership (KTP) sponsored by the Department of Trade and Industry (DTI), and Richmond Pharmacology Ltd is a two year project bringing together academia and commercial expertise.The project will culminate in the development of unique software tools, which will allow for the collection and linking of data from different medical measurement devices into one central repository for analysis.Dr Dilshat Djumanov PhD, a Research Associate from Queen Mary University of London, will undertake this two year research project.Dr Dilshat Djumanov Commented The Knowledge Transfer Partnership gives me the opportunity to undertake a demanding and exciting work based project, in which the results will be implemented in to a commercial environment. Working in conjunction with and having the support from Dr Peter Dabnichki Lecturer in Medical Engineering, Queen Mary University of London, and Dr Radivoj Arezina Research Director, Richmond Pharmacology, this 2 year project will offer Richmond Pharmacology expertise on data acquisition, data processing and software design to compliment and enhance the existing procedures.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more